Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;47(1):7-14.
doi: 10.18773/austprescr.2024.006.

Managing hypercholesterolaemia

Adam J Nelson  1   2   3 , Stephen J Nicholls  1   2   3
Affiliations
Review

Managing hypercholesterolaemia

Adam J Nelson et al. Aust Prescr. 2024 Feb.

Abstract

Hypercholesterolaemia is one of the most common conditions treated by clinicians in Australia. Low-density lipoprotein cholesterol (LDL-C) plays a causal role in the development and progression of atherosclerosis and cardiovascular disease. Every 1 mmol/L reduction in LDL-C concentration is associated with a 21 to 25% reduction in the relative risk of prospective atherosclerotic cardiovascular events, and emerging evidence suggests this benefit increases over time. Absolute cardiovascular risk assessment identifies patients likely to derive the most benefit from lowering LDL-C concentration, and helps determine the intensity of their treatment regimens and targets. Optimal management of LDL-C may require combination treatment with multiple classes of drugs.

Keywords: LDL cholesterol; PCSK9 inhibitors; ezetimibe; hypercholesterolaemia; statins.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Adam Nelson has received research support from Amgen, Boehringer Ingelheim, Novartis and AstraZeneca. Stephen Nicholls has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Fauna Bio, Resverlogix, New Amsterdam Pharmaceuticals, Novartis, InfraReDx and Sanofi-Regeneron. He is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, Cardiol Therapeutics, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Nanophagix, New Amsterdam Pharmaceuticals, Takeda, Pfizer, Sanofi-Regeneron and Novo Nordisk.

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Australian Bureau of Statistics. Australian Health Survey: Users' Guide, 2011-13. Canberra; 2013. https://www.abs.gov.au/ausstats/abs@.nsf/mf/4363.0.55.001 [cited 2023 Dec 20]
    1. Australian Institute of Health and Welfare. Australian Burden of Disease Study 2018: Interactive data on risk factor burden. Canberra; 2018. Last updated 24 November 2021. https://www.aihw.gov.au/reports/burden-of-disease/abds-2018-interactive-... [cited 2023 Dec 20]
    1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-72. 10.1093/eurheartj/ehx144 - DOI - PMC - PubMed
    1. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-30. 10.1093/eurheartj/ehz962 - DOI - PMC - PubMed
    1. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA 2016;316:1289-97. 10.1001/jama.2016.13985 - DOI - PubMed

LinkOut - more resources